oral semaglutide · SEMAGLUTIDE 9 mg/1 · Tablet · Oral · Novo Nordisk Pharmaceutical Industries, LP
NDC 00169-1709-30 · 30 TABLET in 1 BOTTLE, PLASTIC · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
price up 3% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | I-976 | Oct 17, 2028 |
| exclusivity | I-976 | Oct 17, 2028 |
| exclusivity | I-976 | Oct 17, 2028 |
| exclusivity | I-976 | Oct 17, 2028 |
| exclusivity | I-976 | Oct 17, 2028 |
| exclusivity | I-976 | Oct 17, 2028 |
| patent | 12396953 | Feb 1, 2039 |
| patent | 11833248 | Feb 1, 2039 |
| patent | 11833248 | Feb 1, 2039 |
| patent | 11833248 | Feb 1, 2039 |
| patent | 12396953 | Feb 1, 2039 |
| patent | 12396953 | Feb 1, 2039 |
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Novo Nordisk Pharmaceutical Industries, LP | SEMAGLUTIDE 1.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novo Nordisk Pharmaceutical Industries, LP | SEMAGLUTIDE 14 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novo Nordisk Pharmaceutical Industries, LP | SEMAGLUTIDE 3 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novo Nordisk Pharmaceutical Industries, LP | SEMAGLUTIDE 4 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novo Nordisk Pharmaceutical Industries, LP | SEMAGLUTIDE 7 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novo Nordisk Pharmaceutical Industries, LP | SEMAGLUTIDE 9 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Ozempic — NDC 00169-1709-30," retrieved September 3, 2026, https://drugdashboards.com/drug/00169170930.
Free to cite with attribution — see how the data is put together.